The glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP-1) receptor are important targets in the treatment of both type 2 diabetes mellitus (T2DM) and obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.